A- A A+

Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.

Suarez E , Jr, Bartholomew TS, Plesons M, Ciraldo K, Ostrer L, Serota DP, Chueng TA, Frederick M, Onugha J, Tookes HE. 

Ann Med. 2023 Dec;55(1):733-743. doi: 10.1080/07853890.2023.2182908. PMID: 36856571; PMCID: PMC9980015.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980015/

Availability of timely methadone treatment in the United States and Canada during COVID-19: A census tract-level analysis. 

Amram O, Rosenkrantz L, DDes SA, Schuurman N, Panwala VJ, Joudrey PJ. 

Drug Alcohol Depend. 2023 Feb 9;245:109801. doi: 10.1016/j.drugalcdep.2023.109801. Epub ahead of print. PMID: 36801707; PMCID: PMC9908565.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908565/

The development and validation of the pandemic medication-assisted treatment questionnaire for the assessment of pandemic crises impact on medication management and administration for patients with opioid use disorders. 

Leventelis C, Katsouli A, Stavropoulos V, Karasavvidou A, Papadopoulos P, Barmpas PT, Tasoulis S, Veskoukis AS, Tsironi M. 

Nordisk Alkohol Nark. 2023 Feb;40(1):76-94. doi: 10.1177/14550725221135574. Epub 2022 Nov 8. PMID: 36793483; PMCID: PMC9893127.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893127/

Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods.

Molfenter T, Jacobson N, Kim JS, Horst J, Kim H, Madden L, Brown R, Haram E, Knudsen HK. 

J Subst Use Addict Treat. 2023 Feb 10;147:208975. doi: 10.1016/j.josat.2023.208975. Epub ahead of print. PMID: 36804353.

https://www.sciencedirect.com/science/article/pii/S2949875923000255

Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy

Krawczyk, Noa et al.

The Lancet Public Health, Volume 8, Issue 3, e238 - e246 

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(23)00023-3/fulltext

Providing Low-barrier Addiction Treatment Via a Telemedicine Consultation Service During the COVID-19 Pandemic in Los Angeles, County: An Assessment 1 Year Later. 

Kennedy AJ, George JS, Rossetti G, Brown CO, Ragins K, Dadiomov D, Trotzky-Sirr R, Sanchez G, Llamas H, Hurley B. 

J Addict Med. 2023 Jan-Feb 01;17(1):e64-e66. doi: 10.1097/ADM.0000000000001034. Epub 2022 Jul 15. PMID: 35839323; PMCID: PMC9897115.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897115/

Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design. 

Roy PJ, Kim KC, Suda K, Luo J, Wang X, Olejniczak D, Liebschutz JM. 

Drug Alcohol Depend Rep. 2023 Mar;6:100135. doi: 10.1016/j.dadr.2023.100135. Epub 2023 Jan 20. PMID: 36694665; PMCID: PMC9851915.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851915/

Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. 

Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML. 

JAMA Netw Open. 2023;6(1):e2252381. doi:10.1001/jamanetworkopen.2022.52381

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800718

Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder. 

Clingan SE, Cousins SJ, Lin C, Nguyen TE, Hser YI, Mooney LJ. 

Ann Med. 2023 Dec;55(1):480-489. doi: 10.1080/07853890.2023.2169342. PMID: 36692029; PMCID: PMC9879168.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879168/

Discontinuation of Buprenorphine Treatment for Opioid Use Disorder During the Coronavirus Disease-2019 Pandemic: A Multilevel Framework. 

Saloner B, Chang HY, Alexander GC, Stein BD. 

Med Care. 2023 Feb 1;61(2):95-101. doi: 10.1097/MLR.0000000000001802. Epub 2022 Dec 6. PMID: 36630560; PMCID: PMC9830961.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830961/

Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention. 

Stein BD, Landis RK, Sheng F, Saloner B, Gordon AJ, Sorbero M, Dick AW. 

J Gen Intern Med. 2022 Dec 6:1–5. doi: 10.1007/s11606-022-07891-w. Epub ahead of print. PMID: 36474004; PMCID: PMC9734477.

https://link.springer.com/article/10.1007/s11606-022-07891-w

Effect of Didactic Training on Barriers and Biases to Treatment of Opioid Use Disorder: Meeting the Ongoing Needs of Patients with Opioid Use Disorder in the Emergency Department during the COVID-19 Pandemic. 

Johnson E, Bolshakova M, Vosooghi A, Lam CN, Trotzky-Sirr R, Bluthenthal R, Schneberk T. 

Healthcare (Basel). 2022 Nov 29;10(12):2393. doi: 10.3390/healthcare10122393. PMID: 36553917; PMCID: PMC9778275.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778275/

The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study. 

Saunders EC, Satcher MF, Monico LB, McDonald RD, Springer SA, Farabee D, Gryczynski J, Nyaku A, Reeves D, Kunkel LE, Schultheis AM, Schwartz RP, Lee JD, Marsch LA, Waddell EN. 

Health Justice. 2022 Dec 19;10(1):35. doi: 10.1186/s40352-022-00199-1. PMID: 36529829; PMCID: PMC9760540.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760540/

Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory. 

Teck JTW, Zlatkute G, Perez A, Dritschel H, Ghosh A, Potenza MN, Ambekar A, Ekhtiari H, Stein D, Khazaal Y, Arunogiri S, Torrens M, Ferri M, Galea-Singer S, Baldacchino A. 

Lancet Psychiatry. 2023 Jan;10(1):50-64. doi: 10.1016/S2215-0366(22)00374-1. PMID: 36526346.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36526346/

Increasing Use of Video Telehealth Among Veterans Experiencing Homelessness with Substance Use Disorder: Design of A Peer-Led Intervention. 

Garvin LA, Greenan MA, Edelman EJ, Slightam C, McInnes DK, Zulman DM. 

J Technol Behav Sci. 2022 Dec 21:1-12. doi: 10.1007/s41347-022-00290-2. Epub ahead of print. PMID: 36573210; PMCID: PMC9769469.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769469/

Lisbon Addictions 2022. Revised service delivery of opioid agonist treatment in Norway in 2021, the second year of the pandemic: a national cross-sectional study of treatment provider experiences

In Norway, opioid agonist treatment (OAT) clinics had to adapt to more flexible approaches due to the pandemic. The main aim of this study was to explore treatment provider experiences during the second year of the pandemic. (Anne Berit Bech, Lisbon Addictions 2022, Präsentation)

https://www.lisbonaddictions.eu/lisbon-addictions-2022/presentations/1-revised-service-delivery-opioid-agonist-treatment-norway-2021-second-year-pandemic

Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic. 

Kleinman RA, Sanches M. 

Drug Alcohol Depend. 2023 Jan 1;242:109703. doi: 10.1016/j.drugalcdep.2022.109703. Epub 2022 Nov 19. PMID: 36516551; PMCID: PMC9674402.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674402/

Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy. 

Moallef S, DeBeck K, Fairbairn N, Cui Z, Brar R, Wilson D, Johnson C, Milloy MJ, Hayashi K. 

Addict Sci Clin Pract. 2022 Dec 15;17(1):73. doi: 10.1186/s13722-022-00354-x. PMID: 36522789; PMCID: PMC9751503.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751503/

Supporting people affected by problematic alcohol, substance use and other behaviours under pandemic conditions: A pragmatic evaluation of how SMART recovery Australia responded to COVID-19. 

Beck AK, Larance B, Baker AL, Deane FP, Manning V, Hides L, Kelly PJ. 

Addict Behav. 2022 Dec 10;139:107577. doi: 10.1016/j.addbeh.2022.107577. Epub ahead of print. PMID: 36528964; PMCID: PMC9741494.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741494/

Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. 

Lin C, Pham H, Zhu Y, Clingan SE, Lin LA, Murphy SM, Campbell CI, Sorrell TR, Liu Y, Mooney LJ, Hser YI. 

Drug Alcohol Depend. 2022 Nov 23;242:109711. doi: 10.1016/j.drugalcdep.2022.109711. Epub ahead of print. PMID: 36462230.

https://www.sciencedirect.com/science/article/pii/S0376871622004483

Experience and insights from the emergency multiday take-home dose methadone dispensing in Ho Chi Minh City in context of COVD-19. 

Vi VTT, Diep NTN, Han VHN, Van Dung D, Nguyen NLH, Binh LQ, Balhara YPS. 

J Addict Dis. 2022 Nov 30:1-5. doi: 10.1080/10550887.2022.2116254. Epub ahead of print. PMID: 36448505.

Abstract

https://www.tandfonline.com/doi/abs/10.1080/10550887.2022.2116254

The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study. 

Livingston NA, Davenport M, Head M, Henke R, LeBeau LS, Gibson TB, Banducci AN, Sarpong A, Jayanthi S, Roth C, Camacho-Cook J, Meng F, Hyde J, Mulvaney-Day N, White M, Chen DC, Stein MD, Weisberg R. 

Drug Alcohol Depend. 2022 Nov 1;241:109678. doi: 10.1016/j.drugalcdep.2022.109678. Epub ahead of print. PMID: 36368167; PMCID: PMC9624112.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624112/

National trends in buprenorphine prescribing before and during the COVID-19 pandemic. 

Ali MM, Creedon TB, Jacobus-Kantor L, Sherry TB. 

J Subst Abuse Treat. 2023 Jan;144:108923. doi: 10.1016/j.jsat.2022.108923. Epub 2022 Oct 29. PMID: 36334383; PMCID: PMC9617630.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617630/

Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs. 

Krawczyk N, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, Saloner B, Bandara S. 

J Addict Med. 2022 Nov-Dec 01;16(6):645-652. doi: 10.1097/ADM.0000000000000981. PMID: 35165225; PMCID: PMC9653109.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653109/

Triple Threat: Response to the Crises of COVID-19, Homelessness, and Opioid Use Disorder With a Novel Approach to Buprenorphine Delivery: A Case Series. 

Samuel L, Caygill-Walsh R, Suen LW, Mohebbi S, Geier M. 

J Addict Med. 2022 Nov-Dec 01;16(6):733-735. doi: 10.1097/ADM.0000000000000989. PMID: 35245914; PMCID: PMC9653064.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653064/

Impacts of the New York State COVID-19 Disaster Emergency Orders on prescription dispensing for opioids and medication for opioid use disorder. 

Suri A, Feaster DJ, Balise RR, Quinn J, Nunes EV, Gilbert L, El-Bassel N, Rundle AG.

Addiction. 2022 Nov 18. doi: 10.1111/add.16087. Epub ahead of print. PMID: 36398540.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36398540/

HIV Exposure Prophylaxis Delivery in a Low-barrier Substance Use Disorder Bridge Clinic during a Local HIV Outbreak at the Onset of the COVID-19 Pandemic. 

Braun HM, Walter C, Farrell N, Biello KB, Taylor JL. 

J Addict Med. 2022 Nov-Dec 01;16(6):678-683. doi: 10.1097/ADM.0000000000000991. PMID: 36383918; PMCID: PMC9653062.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653062/

Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and Israel. 

Wiessing L, Sypsa V, Abagiu AO, Arble A, Berndt N, Bosch A, Buskin S, Chemtob D, Combs B, Conyngham C, Feelemyer J, Fitzgerald M, Goldberg D, Hatzakis A, Patrascu RE, Keenan E, Khan I, Konrad S, Leahy J, McAuley A, Menza T, Merrick S, Metcalfe R, Rademaker T, Revivo S, Rosca P, Seguin-Devaux C, Skinner S, Smith C, Tinsley J, Wilberg M, Des Jarlais D. 

AIDS Behav. 2022 Nov 11:1–14. doi: 10.1007/s10461-022-03851-x. Epub ahead of print. PMID: 36367613; PMCID: PMC9651099.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651099/

Disruptions to U.S. local public health's role in population-based substance use prevention and response during COVID-19. 

Hall K, Higgins F, Beach KF, Diriba K, Sladky M, McCall TC. 

Subst Abuse Treat Prev Policy. 2022 Nov 7;17(1):73. doi: 10.1186/s13011-022-00499-7. PMID: 36345019; PMCID: PMC9640804.

https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-022-00499-7

Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID. 

Meyerson BE, Bentele KG, Russell DM, Brady BR, Downer M, Garcia RC, Garnett I, Lutz R, Mahoney A, Samorano S, Arredondo C, Andres HJ, Coles H, Granillo B. 

PLoS One. 2022 Oct 25;17(10):e0274094. doi: 10.1371/journal.pone.0274094. PMID: 36282806; PMCID: PMC9595554.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0274094

  1. Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19
  2. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic. 
  3. Drugs and alcohol Use patterns among those seeking care in urban rehabilitation centres before and during early months of COVID-19 in Uganda. 
  4. Sustainment of Contingency Management within Opioid Treatment Programs: COVID-Related Barriers and Innovative Workflow Adaptations. 
  5. Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England.